Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the interim results for the six months ended 30…
Browsing: Essex Bio -Technology Limited
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O),…
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd.…
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai)…
Resilience & Relevance, Growth Ready Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the annual results for…
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited…
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that the first patient in the United States (US)…
Essex Bio-Technology Limited (the Company, together with its subsidiaries, the Group) wishes to announce that Essex Bio-Investment Limited (Essex Bio-Investment),…
Essex Bio-Technology Ltd (EssexBio or the Group, Stock Code: HKG:1061) is pleased and honoured to announce that it is included…
Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million Essex Bio-Technology…